journal article·2025-01Open access

Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles Attenuate Oxidative Damage via the miR-191-5p/DAPK1/AKT Axis in Type 2 Diabetes

Anran Li, Cong Chen, Tongjia Zhang, Yuxin Tian, Yifan Cao, Xiaoming Zhao, Liping Wang

Abstract

Human umbilical cord mesenchymal stem cell extracellular vesicles (hucMSC-EVs) exhibit remarkable potential for alleviating type 2 diabetes mellitus (T2DM). However, the role of hucMSC-EVs in T2DM, particularly concerning oxidative damage to pancreatic β cells, remains underexplored. This study utilized a high-fat diet and streptozotocin (STZ)-induced T2DM mouse model and an STZ-induced INS-1 cell damage model to investigate the effects and mechanisms of hucMSC-EVs. In the T2DM mouse model, hucMSC-EVs effectively lowered blood glucose levels, improved lipid metabolism disorders, and preserved liver function. Moreover, hucMSC-EVs enhanced insulin sensitivity and mitigated oxidative damage. Histological analysis confirmed that hucMSC-EVs marked alleviated liver, kidney, and pancreatic tissue damage. In vitro studies demonstrate that hucMSC-EVs enhance glucose absorption and glycogen synthesis in an insulin-resistant HepG2 model and stimulated insulin secretion in INS-1 cells under high-glucose conditions. In the STZ-induced INS-1 oxidative damage model, hucMSC-EVs protect against oxidative damage by increasing antioxidant enzyme activities, reducing reactive oxygen species production, and decreasing cell apoptosis. The effects were partially mediated by the activation of the phosphatidylinositol 3-kinase (PI3K)/AKT and signal transducer and activator of transcription (STAT) signaling pathways, as well as the up-regulation of key antioxidant proteins such as Nrf2, SOD1, and Bcl2. Further research revealed that miR-191-5p, which is enriched in hucMSC-EVs, targets DAPK1 to activate the PI3K/AKT pathway, thereby contributing to the protective effects against oxidative damage. These findings highlight the critical role and underlying mechanisms of hucMSC-EVs in ameliorating metabolic dysfunction in T2DM, particularly the protective effects against oxidative damage, thus providing a novel strategy for the treatment of T2DM.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · Pancreatic function and diabetes · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

National Engineering Laboratory for AIDS Vaccine, Key Laboratory for Molecular Enzymology and Engineering, the Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China.

Scientific Research Center, China-Japan Union Hospital of Jilin University, Changchun 130012, China.

Funding

the Jilin Province Science and Technology Development Program · the Science and Technology Project of the Jilin Provincial Education Departmen · the Open Project of State Key Laboratory of Supramolecular Structure and Materials

References (46)

Show source-provided references
1. 10.1016/S0140-6736(17)30058-210.1016/S0140-6736(17)30058-2 ↗
2. 10.1038/s41392-024-01951-910.1038/s41392-024-01951-9 ↗
3. 10.1038/nrdp.2015.1910.1038/nrdp.2015.19 ↗
4. 10.1038/nrendo.2017.15110.1038/nrendo.2017.151 ↗
5. 10.2337/diacare.27.1.25610.2337/diacare.27.1.256 ↗
6. Susilawati E, Levita J, Susilawati Y, Sumiwi SA. Review of the case reports on metformin, sulfonylurea, and thiazolidinedione therapies in type 2 diabetes mellitus patients. Med Sci. 2023;11(3):50.
7. 10.1016/j.bbagen.2014.05.01710.1016/j.bbagen.2014.05.017 ↗
8. 10.1016/0891-5849(95)91457-310.1016/0891-5849(95)91457-3 ↗
9. 10.1126/science.106900410.1126/science.1069004 ↗
10. 10.1073/pnas.96.19.1085710.1073/pnas.96.19.10857 ↗
11. 10.1016/j.diabet.2007.03.00510.1016/j.diabet.2007.03.005 ↗
12. 10.1016/j.jep.2024.11834110.1016/j.jep.2024.118341 ↗
13. 10.1007/s13105-020-00770-010.1007/s13105-020-00770-0 ↗
14. 10.1172/JCI1688510.1172/JCI16885 ↗
15. 10.1080/15548627.2023.221398410.1080/15548627.2023.2213984 ↗
16. 10.1371/journal.pone.001572610.1371/journal.pone.0015726 ↗
17. 10.1084/jem.2020141610.1084/jem.20201416 ↗
18. 10.1016/j.phymed.2024.15620210.1016/j.phymed.2024.156202 ↗
19. 10.2337/diabetes.54.7.206010.2337/diabetes.54.7.2060 ↗
20. 10.1186/s13287-024-03636-010.1186/s13287-024-03636-0 ↗
21. 10.4161/cc.10.18.1763810.4161/cc.10.18.17638 ↗
22. 10.1182/blood-2006-12-06341210.1182/blood-2006-12-063412 ↗
23. 10.1186/s13045-015-0181-x10.1186/s13045-015-0181-x ↗
24. 10.7150/thno.2194510.7150/thno.21945 ↗
25. 10.1038/s41392-021-00805-y10.1038/s41392-021-00805-y ↗
26. 10.1016/j.cmet.2020.12.01910.1016/j.cmet.2020.12.019 ↗
27. 10.3390/antiox1310124610.3390/antiox13101246 ↗
28. 10.1016/j.jep.2024.11868410.1016/j.jep.2024.118684 ↗
29. 10.1007/s13770-022-00450-810.1007/s13770-022-00450-8 ↗
30. 10.1021/acschemneuro.2c0042310.1021/acschemneuro.2c00423 ↗
31. 10.1016/j.trsl.2018.08.00310.1016/j.trsl.2018.08.003 ↗
32. 10.1016/j.gene.2024.14831910.1016/j.gene.2024.148319 ↗
33. 10.1210/jcem.86.5.746310.1210/jcem.86.5.7463 ↗
34. 10.1016/j.mrgentox.2021.50343710.1016/j.mrgentox.2021.503437 ↗
35. 10.3109/13813455.2010.55113510.3109/13813455.2010.551135 ↗
36. 10.2174/15672020777994065310.2174/156720207779940653 ↗
37. 10.1152/ajpendo.00429.200110.1152/ajpendo.00429.2001 ↗
38. 10.1016/j.phymed.2024.15602710.1016/j.phymed.2024.156027 ↗
39. 10.1016/j.intimp.2024.11317810.1016/j.intimp.2024.113178 ↗
40. 10.1681/ASN.201307081010.1681/ASN.2013070810 ↗
41. 10.1016/j.intimp.2024.11338510.1016/j.intimp.2024.113385 ↗
42. 10.1016/j.bbrc.2024.15034410.1016/j.bbrc.2024.150344 ↗
43. 10.1080/13813455.2024.240754710.1080/13813455.2024.2407547 ↗
44. 10.1007/s12035-018-1312-510.1007/s12035-018-1312-5 ↗
45. 10.1016/j.cmet.2017.03.01510.1016/j.cmet.2017.03.015 ↗
46. 10.1096/fj.202300847RR10.1096/fj.202300847RR ↗